ABBV AbbVie Inc. Common Stock

65.84
+0.40  (1%)
Previous Close 65.44
Open 65.44
Price To book 20.83
Market Cap 104.79B
Shares 1,591,540,000
Volume 4,676,462
Short Ratio 4.90
Av. Daily Volume 5,970,010

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data at ASCO. Oral Abstract 2003. June 4, 2017.
ABT-414
Recurrent glioblastoma (rGBM)
Phase 3 top-line data due summer 2017. Estimate Aug 31 is last possible date.
ABT-494 - SELECT-BEYOND
Rheumatoid arthritis
Phase 3 trial did not meet primary endpoints - April 19, 2017.
Veliparib
Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC)
Approved November 13, 2013.
Ibrutinib
Relapsed or refractory MCL mantle cell lymphoma
Approved February 12, 2014.
Imbruvica
Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Approved July 19, 2014.
Imbruvica
Deletion 17p
Approved December 19, 2014.
VIEKIRA PAK
HCV - genotype 1
Approved January 29, 2015 - PCYC
IMBRUVICA
Waldenström’s Macroglobulinemia
Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: May 2019
ABBV-8E12
Progressive supranuclear palsy (PSP)
Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: April 2020.
ABBV-8E12
Alzheimer's disease
Phase 3 interim data possibly due 2H 2017.
Imbruvica - PHOENIX
First-line Diffuse large B-cell lymphoma (DLBCL)
Phase 3 data due 2017 as per 1Q earnings call.
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3 trial initiated July 2016. Data due 2019.
Venetoclax
Relapsed or refractory multiple myeloma
Phase 3 trial to commence 2017.
Venclexta
Follicular lymphoma (FL)
Phase 3 trial to commence 2017.
Venclexta
First-line Diffuse large B-cell lymphoma (DLBCL)
Phase 3 trial to commence 2017.
Rova-T
First-line small cell lung cancer (SCLC) maintenance
Phase 3 trial to commence 1H 2017.
Risankizumab
Crohn’s Disease
Phase 3 data due by the end of 2017.
Risankizumab
Psoriasis
Phase 3 initiated in January 2016. Data due late 2017.
Elagolix
Uterine Fibroids
sNDA filing announced April 4, 2017. Assuming priority review would render a PDUFA date of September 4, 2017. Awaiting confirmation of official PDUFA date.
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA Filing due 3Q 2017.
Elagolix
Endometriosis
Phase 3 trial to commence 2017.
ABT-494
Psoriatic Arthritis
Phase 3 top-line data due June 2017.
ABT-494 - SELECT-NEXT
Rheumatoid arthritis
Phase 2b data due 2017.
Risankizumab
Psoriatic Arthritis
Phase 2 positive data at DDW Meeting May 9, 2017. Phase 3 trial to be initiated later in 2017.
ABT-494
Crohn’s Disease
Phase 2 pivotal data due 2017.
Rova-T (TRINITY)
Third-line Small Cell Lung Cancer
Phase 2b data due 2017.
ABT-494
Atopic Dermatitis
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica
Marginal zone lymphoma
Priority review granted February 2, 2017. No PDUFA date supplied. Estimate August 2, 2017.
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)

Latest News

  1. Biotech And Pharma Industry And Stock News
  2. AbbVie Expects Rivals To Chip Away At Its Biggest Drug Franchise
  3. Regeneron, Sanofi Undercut Amgen, AbbVie In Rheumatoid Arthritis
  4. The 3 Best Dividend Stocks in Arthritis Medication
  5. [$$] AmerisourceBergen and AbbVie Top Barron's 500
  6. The Zacks Analyst Blog Highlights: Boeing, AbbVie, UnitedHealth, Consolidated Edison and Cisco
  7. AbbVie to Present at the Jefferies 2017 Global Healthcare Conference
  8. For millions of Chinese with rare diseases, some relief in sight
  9. AbbVie's Humira Loses Patent in Coherus' Petitions
  10. Top 4 Marijuana Stocks to Watch for 2017
  11. New Stock Research Reports for Boeing, AbbVie and UnitedHealth
  12. [$$] AbbVie: It's the Pipeline, Not the Coherus Ruling
  13. AbbVie Down on Humira Patent Loss: Is More Damage in Store?
  14. AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : May 18, 2017
  15. AbbVie Loses Key Humira Patent In Battle With Small-Cap Biotech
  16. AbbVie to Present Latest Clinical Study Results in Hematology and Solid Tumor Research at the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting
  17. Humira Ruling Is A 'Big Victory' For Coherus
  18. Why This Humira Patent Loss Might Not Be What You Think
  19. AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis
  20. AbbVie Stock Lower on Humira Patent Ruling